Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

被引：16

作者：

Modi, S. ^{[1
]}

Jacot, W. ^{[2
]}

Iwata, H. ^{[3
]}

Park, Y. H. ^{[4
]}

Vidal Losada, M. J. ^{[5
]}

Li, W. ^{[6
]}

Tsurutani, J. ^{[7
]}

Zaman, K. ^{[8
]}

Ueno, N. T. ^{[9
]}

Prat, A. ^{[10
]}

Papazisis, K. ^{[11
]}

Rugo, H. S. ^{[12
]}

Harbeck, N. ^{[13
]}

Im, S-A. ^{[14
]}

De Laurentiis, M. ^{[15
]}

Orbegoso, C. M. A. ^{[16
]}

Yung, L. ^{[17
]}

Cheng, F-C. ^{[18
]}

Cheng, Y. ^{[19
]}

Cameron, D. A. ^{[20
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA

[2] Inst Canc Montpellier, Med Oncol, Montpellier, France

[3] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan

[4] Samsung Med Ctr, Hematol Oncol, Seoul, South Korea

[5] Hosp Clin Barcelona, Oncol Med, Barcelona, Spain

[6] First Hosp Jilin Univ, Tumor Ctr, Changchun, Jilin, Peoples R China

[7] Showa Univ, Adv Canc Translat Res Inst, Shinagawa, Japan

[8] Lausanne Univ Hosp CHUV, Oncol, Lausanne, Switzerland

[9] Univ Hawaii, Med, Ctr Canc, Honolulu, HI USA

[10] August Pi & Sunyer Biomed Res Inst IDIBAPS, Med Oncol, Translat Genom & Targeted Therapies Grp, Barcelona, Spain

[11] Euromed Gen Clin, Oncol, Thessaloniki, Greece

[12] UCSF, Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[13] LMU Univ Hosp, Breast Ctr, Obstet & Gynecol, Munich, Germany

[14] Seoul Natl Univ, Seoul Natl Univ Hosp, Internal Med, Coll Med, Seoul, South Korea

[15] Ist Nazl Tumori IRCCS Fdn G Pascale, Breast Oncol Unit, Naples, Italy

[16] Daiichi Sankyo Inc, Global Oncol Res & Dev, Rueil Malmaison, France

[17] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA

[18] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA

[19] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA

[20] Univ Edinburgh, Edinburgh Univ Canc Ctr, Edinburgh, Midlothian, Scotland

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.553

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

376O

引用

页码：S334 / S335

页数：2

共 50 条

[21] Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
Hamilton, Erika P.
Petry Helena, Vanessa Bragaia
Yeo, Bragaia Winnie
Kim, Sung-Bae
Bianchini, Giampaolo
Yamashita, Toshinari
Yonemori, Kan
Inoue, Kenichi
Curigliano, Giuseppe
Hurvitz, Sara A.
Cortes, Javier
Iwata, Hiroji
Cathcart, Jillian
Liu, Yali
Lee, Caleb C.
Bako, Emarjola
Kim, Rachel
Im, Seock-Ah
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[22] Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
Zhan, Mei
Huang, Zijia
Xu, Ting
Xu, Xinyi
Zheng, Hanrui
Wu, Fengbo
FRONTIERS IN PUBLIC HEALTH, 2023, 11
[23] Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study
Modi, Shanu
FUTURE ONCOLOGY, 2025, 21 (04) : 367 - 380
[24] Approval study DESTINY-Breast04 convinces in new category trastuzumab-deruxtecan: First targeted therapy for metastatic HER2-low breast cancer
Fessler, Beate
BREAST CARE, 2023, 18 (02)
[25] Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06
Hu, X.
Curigliano, G.
Yonemori, K.
Bardia, A.
Barrios, C. H. E.
Sohn, J.
Levy, C.
Jacot, W.
Tsurutani, J.
Mezei, K.
de Climens, A. Roborel
Wu, X.
Begbie, N.
Mbanya, Z.
Dent, R. A.
ANNALS OF ONCOLOGY, 2024, 35 : 1214 - 1215
[26] Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03
Hurvitz, Sara
Hegg, Roberto
Chung, Wei-Pang
Im, Seock-Ah
Jacot, William
Ganju, Vinod
Chiu, Joanne Win Yang
Xu, Binghe
Hamilton, Erika
Madhusudan, Srinivasan
Iwata, Hiroji
Altintas, Sevilay
Henning, Jan-Willem
Curigliano, Giuseppe
Perez-Garcia, Jose Manuel
Egorov, Anton
Liu, Yali
Cathcart, Jillian
Ashfaque, Shahid
Cortes, Javier
CANCER RESEARCH, 2023, 83 (05)
[27] Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
Curigliano, G.
Dunton, K.
Rosenlund, M.
Janek, M.
Cathcart, J.
Liu, Y.
Fasching, P. A.
Iwata, H.
ANNALS OF ONCOLOGY, 2022, 33 : S196 - S197
[28] Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
Guarneri, Valentina
Coelho, Jose Luis Passos
Duhoux, Francois P.
Egle, Daniel
Garcia-Saenz, Jose angel
Penault-Llorca, Frederique
Selander, Katri
Wildiers, Hans
Zaman, Khalil
Laeis, Petra
Lucerna, Markus
Pierga, Jean-Yves
FUTURE ONCOLOGY, 2024, 20 (18) : 1237 - 1250
[29] Trastuzumab Deruxtecan vs Physician's Choice in Patients With HER2+ Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine: Primary Results of the Randomized, Phase 3 Study DESTINY-Breast02
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 7 - 7
[30] Trastuzumab deruxtecan vs physician's choice in patients with HER2+unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02
Krop, Ian
Park, Yeon H.
Kim, Sung-Bae
Borges, Giuliano
Aksoy, Sercan
Gregori, Joaquin Gavila
Roylance, Rebecca
Lim, Elgene
Yerushalmi, Rinat
Zagouri, Flora
Duhoux, Francois P.
Fehm, Tanja
Takano, Toshimi
Egorov, Anton
Wu, Iris
Cathcart, Jillian
Chu, Changan
Andre, Fabrice
CANCER RESEARCH, 2023, 83 (05)

← 1 2 3 4 5 →